Castle Biosciences CSTL Business Segments — Long-lived assets, expenditure

Similar metrics at other companies

LLYReportable Segment — Expenditures for long-lived assets

$2.44B+60.7%

VGN

VGNTReportable Segment — Segment, Expenditure, Addition to Long-Lived Assets

$66M+78.4%

RXRXReportable Segment — Total expenditures for additions to long-lived assets

$258K-91.3%

BIIBReportable Segment — Other long-lived assets

$3.32B-6.1%

NFGTotal Reportable Segments — Expenditures for Additions to Long-Lived Assets

$233.25M+29.0%

GHC

GHCReportable Segment, Aggregation before Other Operating Segment — Segment, Expenditure, Addition to Long-Lived Assets

$17.37M+84.6%

Questions, answered.

What is Castle Biosciences's business segments — long-lived assets, expenditure?

Castle Biosciences (CSTL) reported business segments — long-lived assets, expenditure of $5.2M in Q1 2026.

How has Castle Biosciences's business segments — long-lived assets, expenditure changed year-over-year?

Castle Biosciences's business segments — long-lived assets, expenditure decreased by 8.8% year-over-year, from $5.7M to $5.2M.

What is the long-term trend for Castle Biosciences's business segments — long-lived assets, expenditure?

Over 3 years (2022 to 2025), Castle Biosciences's business segments — long-lived assets, expenditure has grown at a 86.1% compound annual growth rate (CAGR), from $7M to $45.1M.

What does business segments — long-lived assets, expenditure mean?

This represents the capital investment made by the segment to acquire or upgrade physical and long-term assets necessary for business operations. It indicates the segment's commitment to scaling its diagnostic capabilities and long-term growth infrastructure.